Longmont, CO – According to filings with the U.S. Securities and Exchange Commission, KromaTiD is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nathan Wood played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About KromaTiD
KromaTiD provides innovative solutions for the discovery, detection and quantification of genomic structural variations. With our dGH platform, we are able to observe gene editing-associated rearrangements in their chromosomal structural context. The data is complementary to sequencing and our assays provide researchers and innovators in gene editing with an additional dimension of data to support optimization of process variables, quantitation of structural off-target effects, and tracking of durable genomic changes over time. KromaTiD next-gen cytogenetic products focused on discovering, detecting, and diagnosing genomic rearrangements in the areas of oncology and rare diseases. The companys molecular cytogenetic and GeneTracker tests discover, detect, and diagnose the widest range of disease-causing mutations, including inversions and translocations, in a single test, enabling researchers and medical professionals to detect and diagnose diseases easily.

To learn more about KromaTiD, visit http://www.kromatid.com/

Contact:
Nathan Wood, Chief Executive Officer
303-775-1512
nwood@kromatid.com
https://www.linkedin.com/in/nathan-wood-849b20171/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved